Japan Long-term Safety for Tiotropium Plus Olodaterol

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tiotropium + Olodaterol

Tiotropium and Olodaterol FDC once daily inhalation

DEVICE

Respimat

Respimat inhaler

DRUG

Tiotropium + Olodaterol

Tiotropium and Olodaterol FDC once daily inhalation

DRUG

Olodaterol

Olodaterol once daily inhalation

DEVICE

Respimat

Respimat inhaler

DEVICE

Respimat

Respimat inhaler

Trial Locations (24)

Unknown

1237.22.81015 Boehringer Ingelheim Investigational Site, Chiyoda-ku, Tokyo

1237.22.81023 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo

1237.22.81009 Boehringer Ingelheim Investigational Site, Hamamatu, Shizuoka

1237.22.81011 Boehringer Ingelheim Investigational Site, Kishiwada, Osaka

1237.22.81007 Boehringer Ingelheim Investigational Site, Komatsu, Ishikawa

1237.22.81028 Boehringer Ingelheim Investigational Site, Koriyama, Fukushima

1237.22.81019 Boehringer Ingelheim Investigational Site, Koto-ku,Tokyo

1237.22.81021 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto

1237.22.81014 Boehringer Ingelheim Investigational Site, Minami-ku, Kumamoto, Kumamoto

1237.22.81017 Boehringer Ingelheim Investigational Site, Morioka, Iwate

1237.22.81004 Boehringer Ingelheim Investigational Site, Nagaoka, Niigata

1237.22.81029 Boehringer Ingelheim Investigational Site, Nagasaki, Nagasaki

1237.22.81027 Boehringer Ingelheim Investigational Site, Osakasayama, Osaka

1237.22.81008 Boehringer Ingelheim Investigational Site, Saku, Nagano-ken

1237.22.81001 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1237.22.81016 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1237.22.81022 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1237.22.81025 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1237.22.81018 Boehringer Ingelheim Investigational Site, Setagaya-ku, Tokyo

1237.22.81026 Boehringer Ingelheim Investigational Site, Tagajyo,Miyagi

1237.22.81010 Boehringer Ingelheim Investigational Site, Takatsuki, Osaka

1237.22.81020 Boehringer Ingelheim Investigational Site, Toyohashi, Aichi

1237.22.81030 Boehringer Ingelheim Investigational Site, Unzen, Nagasaki

1237.22.81003 Boehringer Ingelheim Investigational Site, Yokohama,Kanagawa

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01536262 - Japan Long-term Safety for Tiotropium Plus Olodaterol | Biotech Hunter | Biotech Hunter